Heart failure (HF) is a leading cause of morbidity and mortality worldwide. A small proportion
of HF cases are attributable to monogenic cardiomyopathies and existing genome-wide …

Background: Cancer therapy–induced cardiomyopathy (CCM) is associated with cumulative
drug exposures and preexisting cardiovascular disorders. These parameters incompletely …

Hypertrophic cardiomyopathy (HCM) is often caused by pathogenic variants in sarcomeric
genes and characterized by left ventricular (LV) hypertrophy, myocardial fibrosis and …

Arrhythmogenic cardiomyopathy (ACM) is a primary disease of the myocardium, predominantly
caused by genetic defects in proteins of the cardiac intercalated disc, particularly, …

Pathogenic mutations in LAMIN A/C (LMNA) cause abnormal nuclear structure and
laminopathies. These diseases have myriad tissue-specific phenotypes, including dilated …

Objectives : This study sought to determine the extent, time course, and predictors of
improvement following cardiac resynchronization therapy (CRT) upgrade among pacing-induced …

Importance Mavacamten, a cardiac myosin inhibitor, improved peak oxygen uptake (pVO 2 )
in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in the …

Aims Risk stratification algorithms for sudden cardiac death (SCD) in hypertrophic
cardiomyopathy (HCM) and regional differences in clinical practice have evolved over time. We …

Background COVID-19 continues to inflict significant morbidity and mortality, particularly on
patients with preexisting health conditions. The clinical course, outcomes, and significance of …

Background: There is a paucity of data regarding the phenotype of dilated cardiomyopathy (DCM)
gene variants in the general population. We aimed to determine the frequency and …